PR Newswire - Celltrion announces publication of post-hoc analys...
Findings from the post-hoc analysis of LIBERTY-CD study indicates efficacy of ZYMFENTRA® (subcutaneous infliximab) regardless of disease location, consistent across ileum-dominant and colon-do...
Read More

ภาษาไทย
English